Apomorphine (Apokyn)

Apokyn (apomorphine) is covered only for the FDA‑approved use — acute, intermittent treatment of hypomobility "off" episodes in advanced Parkinson’s disease — and is not covered for non‑FDA indications. Coverage requires documented advanced PD with "off" episodes, current carbidopa/levodopa therapy, prior trials of ≥2 other "off" treatments, prescription by or consultation with a neurologist, authorization limited to 12 months, subcutaneous administration only, and dosing titrated from 2 mg (0.2 mL) up to 6 mg (0.6 mL) per dose.

"Acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) with advanced Parkinson's disease (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.